What's breaking now, across thousands of outlets.
A Shanghai and Boston biotech led by a veteran transpacific drug developer has secured more than $80 million to advance three clinical-stage brain-health drugs. NeuShen Therapeutics disclosed the Series B this ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Ionis Pharmaceuticals got FDA approval of its rare neurodegenerative disease treatment zilganersen, paving the way for the company’s first wholly owned neurology product.
Today, treatment decisions for patients with mantle cell lymphoma are heavily based on age alone, although the disease can range from slow-growing (indolent) to very aggressive.
Of 11 clinics contacted by CNA, three said they had run out of the Southern Hemisphere vaccine, while another said it had little stock left amid a rise in demand for flu jabs.
‘Medical aid schemes are effectively 20% to 30% more expensive because we never made it mandatory for employed people to belong to medical schemes,’ says Thoneshan Naidoo, CEO of the Health Funders…
Pop-up messages that warn of the harms of social media—such as mental health consequences—have the potential to reduce young people's social media use, a new Stanford Medicine study has found.
